Get the Stockscreener App
82.27
2.27%
-1.91
After Hours:
83.49
1.22
+1.48%
Protagonist Therapeutics Inc stock is traded at $82.27, with a volume of 700.93K.
It is down -2.27% in the last 24 hours and down -8.23% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$84.18
Open:
$83.25
24h Volume:
700.93K
Relative Volume:
0.65
Market Cap:
$5.14B
Revenue:
$209.18M
Net Income/Loss:
$52.04M
P/E Ratio:
115.47
EPS:
0.7125
Net Cash Flow:
$37.10M
1W Performance:
-5.72%
1M Performance:
-8.23%
6M Performance:
+61.16%
1Y Performance:
+115.99%
1-Day Range:
$81.67
$85.00
1-Week Range:
$81.67
$88.23
52-Week Range:
$33.70
$96.54
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
82.27 | 5.26B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-12-25 | Initiated | Leerink Partners | Outperform |
| Jun-17-25 | Initiated | Citigroup | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Protagonist (PTGX) Stock Pre-Market (-6.4%): NDA Submission For Rusfertide Triggers Sell-The-News - Trefis
Protagonist Therapeutics (PTGX) Target Price Raised by Truist Se - GuruFocus
Truist raises Protagonist Therapeutics stock price target to $110 on pivotal year ahead - Investing.com Canada
(PTGX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Moody Aldrich Partners LLC Sells 27,510 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Galesburg Register Mail
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - The Coloradoan
Protagonist Therapeutics Earnings Notes - Trefis
Protagonist Therapeutics Advances Pipeline Amid Financial Loss - MSN
Exchange Traded Concepts LLC Sells 13,839 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
(PTGX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by Voya Investment Management LLC - MarketBeat
Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Daytona Beach News-Journal
Aug Selloffs: Why Protagonist Therapeutics Inc stock is recommended by analystsJuly 2025 Pullbacks & Smart Allocation Stock Reports - moha.gov.vn
Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX) - The Globe and Mail
Can Protagonist Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Chart Watch & Growth Focused Stock Reports - DonanımHaber
Will Protagonist Therapeutics Inc. stock remain a Wall Street favoriteWeekly Trade Summary & Low Risk Investment Opportunities - DonanımHaber
Why Protagonist Therapeutics Inc. stock is favored by top institutionsPortfolio Risk Report & Fast Gain Stock Tips - DonanımHaber
How Protagonist Therapeutics Inc. stock benefits from strong dollar2025 Risk Factors & Real-Time Volume Spike Alerts - DonanımHaber
Is Protagonist Therapeutics Inc. stock a contrarian buyChart Signals & Consistent Income Trade Recommendations - Улправда
Why Protagonist Therapeutics Inc. stock is recommended by analysts2025 Volatility Report & Reliable Volume Spike Trade Alerts - Улправда
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Down 5.6%Should You Sell? - MarketBeat
Barclays Maintains Protagonist Therapeutics (PTGX) Overweight Recommendation - Nasdaq
Protagonist Therapeutics (PTGX) Target Price Raised by Barclays - GuruFocus
How Investors Are Reacting To Protagonist Therapeutics (PTGX) Rusfertide’s Pivotal Phase 3 VERIFY Results - Sahm
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Green Bay Press-Gazette
Three Stocks That May Be Undervalued In December 2025 - Sahm
Valuing Protagonist Therapeutics (PTGX) After New 52-Week Phase 3 VERIFY Data on Rusfertide - Sahm
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year HighWhat's Next? - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by BVF Inc. IL - MarketBeat
683 Capital Management LLC Reduces Stake in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock hits all-time high at 93.53 USD By Investing.com - Investing.com Australia
Protagonist Therapeutics stock hits all-time high at 93.53 USD - Investing.com India
Citizens maintains Protagonist Therapeutics stock rating, citing rusfertide efficacy By Investing.com - Investing.com Canada
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $803,000 Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Natixis Purchases Shares of 42,040 Protagonist Therapeutics, Inc. $PTGX - MarketBeat
VIX Spike: How Protagonist Therapeutics Inc stock benefits from strong dollar2025 Winners & Losers & Fast Entry Momentum Trade Alerts - moha.gov.vn
How (PTGX) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
HighVista Strategies LLC Lowers Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
High Growth Tech Stocks In The US Market With Potential - Yahoo Finance
Stempoint Capital LP Trims Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Diadema Partners LP Makes New $4.21 Million Investment in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Daily Comet
Polycythemia Vera Clinical Trial Pipeline Shows Potential with Active Contributions from 8+ Key Companies | DelveInsight - The Globe and Mail
Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq
PTGX Stock Receives Positive Analyst Rating Update from Citigrou - GuruFocus
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Is Rusfertide’s Phase 3 VERIFY Durability Data Altering The Investment Case For Protagonist Therapeutics (PTGX)? - Sahm
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Oct 10 '25 |
Option Exercise |
6.98 |
12,000 |
83,760 |
17,130 |
| Waddill William D. | Director |
Oct 10 '25 |
Sale |
81.62 |
12,000 |
979,480 |
5,130 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):